Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.92+0.22 (+3.86%)
Close on Nov 18, 2026Market cap $769.50MP/E –Yield –
Cytek Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cytek Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$44.65M. For fiscal 2025 it was -$40.38M. The highest annual figure on record is $13.66M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$40.38M | – |
| FY2024 | Dec 31, 2024 | -$20.52M | – |
| FY2023 | Dec 31, 2023 | -$27.85M | – |
| FY2022 | Dec 31, 2022 | -$1.80M | -119.7% |
| FY2021 | Dec 31, 2021 | $9.16M | -33.0% |
| FY2020 | Dec 31, 2020 | $13.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.59M | -287.3% |
| Q3 FY2025 | Sep 30, 2025 | -$9.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.98M | – |
| Q4 FY2024 | Dec 31, 2024 | $2.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.25M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$137.00K | -263.1% |
| Q3 FY2023 | Sep 30, 2023 | -$6.42M | -572.1% |
| Q2 FY2023 | Jun 30, 2023 | -$9.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.16M | – |
| Q4 FY2022 | Dec 31, 2022 | $84.00K | -93.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.36M | -53.1% |
| Q2 FY2022 | Jun 30, 2022 | -$891.00K | -123.4% |
| Q1 FY2022 | Mar 31, 2022 | -$2.36M | -308.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.32M | -83.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.90M | -56.8% |
| Q2 FY2021 | Jun 30, 2021 | $3.81M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.13M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.88M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$218.00K | – |
See a number that looks wrong?